230 related articles for article (PubMed ID: 33288843)
1. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
Liu S; Shen M; Hsu EC; Zhang CA; Garcia-Marques F; Nolley R; Koul K; Rice MA; Aslan M; Pitteri SJ; Massie C; George A; Brooks JD; Gnanapragasam VJ; Stoyanova T
Br J Cancer; 2021 Mar; 124(5):896-900. PubMed ID: 33288843
[TBL] [Abstract][Full Text] [Related]
2. Pleiotrophin as a potential biomarker in breast cancer patients.
Ma J; Kong Y; Nan H; Qu S; Fu X; Jiang L; Wang W; Guo H; Zhao S; He J; Nan K
Clin Chim Acta; 2017 Mar; 466():6-12. PubMed ID: 28041942
[TBL] [Abstract][Full Text] [Related]
3. Serum pleiotrophin as a diagnostic and prognostic marker for small cell lung cancer.
Xu C; Wang Y; Yuan Q; Wang W; Chi C; Zhang Q; Zhang X
J Cell Mol Med; 2019 Mar; 23(3):2077-2082. PubMed ID: 30635982
[TBL] [Abstract][Full Text] [Related]
4. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
Du ZY; Shi MH; Ji CH; Yu Y
Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
[TBL] [Abstract][Full Text] [Related]
5. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
6. Pleiotrophin serum level and metastasis occurrence in breast cancer patients.
Ikhlas M; Ferianto D; Syamsu SA; Ganda IJ; Smaradania N; Sampepajung E; Anggita CA; Faruk M
Breast Dis; 2024; 43(1):93-98. PubMed ID: 38701136
[TBL] [Abstract][Full Text] [Related]
7. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
8. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
Kurose H; Ueda K; Kondo R; Ogasawara S; Kusano H; Sanada S; Naito Y; Akiba J; Kakuma T; Igawa T; Yano H
Anticancer Res; 2019 Feb; 39(2):957-964. PubMed ID: 30711981
[TBL] [Abstract][Full Text] [Related]
10. TRIM24 as an independent prognostic biomarker for prostate cancer.
Offermann A; Roth D; Hupe MC; Hohensteiner S; Becker F; Joerg V; Carlsson J; Kuempers C; Ribbat-Idel J; Tharun L; Sailer V; Kirfel J; Svensson M; Andren O; Lubczyk V; Kuefer R; Merseburger AS; Perner S
Urol Oncol; 2019 Sep; 37(9):576.e1-576.e10. PubMed ID: 31178279
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
[TBL] [Abstract][Full Text] [Related]
12. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
14. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells.
Laursen EB; Fredsøe J; Schmidt L; Strand SH; Kristensen H; Rasmussen AKI; Daugaard TF; Mouritzen P; Høyer S; Kristensen G; Stroomberg HV; Brasso K; Røder MA; Borre M; Sørensen KD
Am J Pathol; 2019 Dec; 189(12):2377-2388. PubMed ID: 31539518
[TBL] [Abstract][Full Text] [Related]
15. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
17. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
[TBL] [Abstract][Full Text] [Related]
18. The preoperative neutrophil-to-lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy.
Cao Z; Ji J; Zhang C; Wang F; Xu H; Yu Y; Sun Y
Cancer Med; 2019 Mar; 8(3):1004-1012. PubMed ID: 30693666
[TBL] [Abstract][Full Text] [Related]
19. Role of serum cholinesterase in patients treated with salvage radical prostatectomy.
Vartolomei MD; D'Andrea D; Chade DC; Soria F; Kimura S; Foerster B; Abufaraj M; Mathieu R; Moschini M; Rouprêt M; Briganti A; Karakiewicz PI; Shariat SF
Urol Oncol; 2019 Feb; 37(2):123-129. PubMed ID: 30522902
[TBL] [Abstract][Full Text] [Related]
20. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer.
Han M; Piantadosi S; Zahurak ML; Sokoll LJ; Chan DW; Epstein JI; Walsh PC; Partin AW
Urology; 2001 Apr; 57(4):707-11. PubMed ID: 11306387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
